Urinary Tract Infections, Prostatitis, Interstitial Cystitis
Conditions
Keywords
UTI, IC
Brief summary
In this protocol, investigators are examining the ability for a novel multiplex PCR assay with mixed floral antibiotic resistance profiling is safe and increases effective treatment for urinary tract infections in a urology clinic over traditional culture methods alone and decreases retreatment rates in this population.
Detailed description
The novel multiplex real-time PCR assay with mixed floral antibiotic resistance profiling offers a higher degree of sensitivity and specificity than conventional culture methods in the identification of UTI pathogens as determined by the previous prospective comparison study. Additionally, conventional methods are often inadequate in the case of polymicrobial infections. More accurate and timely pathogen identification allows for prompt and more targeted treatment with less reliance on empiric therapy and decreased rates of antibiotic therapy changes and retreatment. This leads to more favorable patient outcomes and decreases the development of resistant organisms.
Interventions
DIAGNOSTIC_TESTGuidance 4.0 PCR test
All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.
DIAGNOSTIC_TESTUrine Culture
All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.
Sponsors
Comprehensive Urology-a Division of Michigan Healthcare Professionals
Pathnostics
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Caregiver)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* • Patient Informed Consent form completed * Male and Female Subjects may participate with no predetermined quotas or ratios for gender participation. * All patients must be ≥60 years old. For patients presenting with a diagnosis of interstitial cystitis, patients may be of any age. * Patients must be presenting for treatment of acute UTI, complicated UTI, persistent UTI, or recurrent UTI's. * Including prostatitis, pyelonephritis, and/or interstitial cystitis. * Data pertaining to the times at which the specimen samples are collected and stabilized needs to be documented. * Specimen samples obtained need to have a sufficient volume necessary to perform a urine culture and Guidance 4.0.
Exclusion criteria
* • Do not provide written informed Consent with HIPAA authorization form. * Taking antibiotics for any reason other than UTI at the time of enrollment * Patients with chronic (\> 10 days) indwelling catheters * Self-catheterized patients * Patients with neobladders
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Establish Safety: composite adverse event rate | 7 Days | Demonstrate safety of Guidance 4.0 multiplex real-time PCR organism identification with mixed floral antibiotic resistance profiling guided treatment. Safety will be measured with a composite adverse event outcome of urosepsis, pyelonephritis, hospitalization, or the need to attend an urgent care center. The composite adverse event rate in the arm tested with Guidance 4.0 will be shown to be non-inferior to that in the arm tested with traditional urine culture. Superiority will also be tested. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients with Recurrent and Persistent Infections in Each Arm | 7 Days | Demonstrate non-inferiority and possibly superiority of Guidance 4.0 over traditional urine C&S with respect to the percentage of recurrent and persistent infections. Persistent is remaining infection at day 7 and recurrent infection is a person that had a second infection within 30 days that was treated with antibiotics. |
| Time to Symptom Resolution in Each Arm | 7 days | Demonstrate superiority of Guidance 4.0 over traditional urine C&S with respect to the time to symptom resolution as demonstrated by UTISA tool. Symptom resolution will be defined as an overall rating of no symptoms on the UTISA questionnaire. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Physician Choice for Decision Making when Provided Both Results | 4 Months | • To determine which test physicians, rely upon when given the results of both traditional urine C&S vs. Guidance 4.0. |
Countries
United States
Outcome results
None listed